A Phase 1, Open-Label Adaptive Design Study To Evaluate PDE10 Enzyme Occupancy As Measured By Positron Emission Tomography (PET) Following Single Oral Dose Administration Of PF-02545920 In Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 01 May 2017
At a glance
- Drugs Mardepodect (Primary)
- Indications Huntington's disease; Schizophrenia
- Focus Pharmacodynamics
- Sponsors Pfizer
- 09 Nov 2014 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 07 Oct 2014 Planned number of patients changed from 12 to 15, as reported by ClinicalTrials.gov.
- 07 Jul 2014 Planned End Date changed from 1 Aug 2014 to 1 Nov 2014, as per ClinicalTrials.gov record.